XOMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Xoma Royalty Corp (XOMA) is not a good buy for a beginner investor with a long-term strategy at this time. The pending acquisition by Ligand Pharmaceuticals at $39 per share in cash limits the upside potential, and the stock is trading slightly above this price. There are no significant trading signals or positive catalysts to justify an investment.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 54.193, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 41.935, with limited movement expected based on support and resistance levels.
The company announced cash dividends for preferred stockholders and plans to redeem all outstanding preferred stock as part of its merger with Flex Merger Sub, Inc.
The pending acquisition by Ligand Pharmaceuticals at $39 per share in cash caps the stock's upside potential. Analysts have downgraded the stock to Neutral, citing the acquisition.
No financial data available for analysis.
Analysts have downgraded XOMA to Neutral from Buy, with a price target of $39, citing the pending acquisition by Ligand Pharmaceuticals. This indicates limited growth potential for the stock.
